期刊文献+

四硫化四砷联合维甲酸、蒽环类药物治疗体系下附加染色体对急性早幼粒细胞白血病预后的影响 被引量:5

Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracycfin based protocol
原文传递
导出
摘要 目的分析在以维甲酸联合四硫化四砷、蒽环类药物为主的治疗体系下附加染色体对预后的影响以及有附加染色体异常患者的临床表现和对含四硫化四砷诱导治疗方案的反应性。方法回顾性分析158例初治急性早幼粒细胞白血病患者临床资料。结果附加染色体异常在急性早幼粒细胞白血病中占18.4%。其中三体8以及i17q-是最常见的附加异常,有附加染色体异常组患者弥散性血管内凝血发生率增高(P〈0.05)。在附加染色体异常组完全缓解率降低(75.9%vs90.7%)、复发率增高(13.8%vs6.2%)、中枢神经系统白血病的发生率增高(17.2%VS6.2%),但差异未见统计学意义。两组生存率差异无统计学意义(P=0.160)。结论在此三类药物治疗体系下,尚未发现附加染色体对预后影响的统计学意义。 Objective To analyze the effect of additional chromosome abnormalities on the prognosis and the clinical manifestations of acute promyelocytic leukemia (APL) and the reaction of the patients with additional chromosomes to the treatment of combination of red arsenic sulfide, all trans-retinoic acid (ATRA) and anthracyclin. Methods The clinical data of 158 patients with newly diagnosed APL who were treated with combination of red arsenic sulfide, ATRA, and anthracyclin were analyzed retrospectively. Results The frequency of additional chromosome abnormalities in the APL patients was 18. 4%, and trisome 8 and ilTq- were the most to be seen. The disseminated intravascular coagulation rate of the patients with additional chromosome abnormality was 62. 1%, significantly higher than that of the patients without additional chromosome abnormality (35.6%, P 〈 0.05 ). The complete remission rate of the patients with additional chrosome abnormality was 75.9%, not significantly lower than that of those without additional chrosome abnormality (90. 7% ), and the relapse rate and incidence rate of central nervous system leukemia were 13.8% and 17.2%, both higher, but not significantly, than those of the patients without additional chromosome abnormality ( 6. 2% and 6. 2% respectively ) ( all P 〉 0. 05 ). There was no significant difference in survival rate between these 2 groups ( P = 0. 160 ). Conclusion Additional chromosome abnormality does not significantly influence the prognosis of APL treated with combination of red arsenic sulfide, ATRA, and anthracyclin.
出处 《中华医学杂志》 CAS CSCD 北大核心 2008年第32期2254-2257,共4页 National Medical Journal of China
基金 国家“863”高技术研究发展计划基金资助项目(2006AA02A405) 教育部创新团队基金资助项目(IRT0702)
关键词 白血病 髓样 维甲酸 抗生素类 蒽环 染色体 四硫化四砷 Leukemia, myeloid Tretinoin Antibiotics, anthracycline Chromosomes Red arsenic sulfide
  • 相关文献

参考文献12

  • 1Zhou GB, Zhang J, Wang ZY, et al . Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci, 2007,362:959-971.
  • 2Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia : a pilot report. Blood, 2002,99:3136-3143.
  • 3鲍立,江滨,王德炳,陈珊珊,邱镜滢,卢锡京,黄晓军,陆道培.高白细胞急性早幼粒细胞白血病的临床研究[J].中国综合临床,2007,23(7):606-608. 被引量:5
  • 4丘镜滢,党辉,任汉云,王德炳,段爱君.自体血浆培养体系对改善白血病骨髓细胞染色体的研究[J].北京医科大学学报,1993,25(4):249-251. 被引量:46
  • 5卞寿庚.急性髓性白血病分型诊断标准//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:106-115.
  • 6秘营昌,卞寿庚.急性白血病疗效标准//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:131-132.
  • 7Xu L, Zhao WL, Xiong SM, et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/ or variant chromosome abnormalities in acute promyetocytic leukemia. Leukemia,2001,15 : 1359-1368.
  • 8肖溶,张日.55例急性早幼粒细胞白血病形态学、细胞免疫学、细胞遗传学及分子生物学(MICM)分型的回顾性分析[J].中国实验血液学杂志,2004,12(2):147-150. 被引量:13
  • 9Hernandez JM, Martin G, Gutierrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica,2001,86:807-813.
  • 10Chou WC, Tang JL, Yao M, et al. Clinical and biological characteristics of acute promyelocytlc leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia, 1997, 11:921-928.

二级参考文献19

  • 1何徐彭,徐开林,鹿群先,潘秀英,黄一虹,何祎.砷剂与化疗双诱导治疗急性早幼粒细胞白血病疗效观察[J].中华血液学杂志,2004,25(12):759-760. 被引量:3
  • 2Orfao A, Chillon MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica,1999;84:405-412
  • 3Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood,1991;78:1413-1419
  • 4Bennet JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukemia(M3). Ann Intern Med,1980;92(2pt1):261
  • 5Basso G, Buldini B, De Zen L, et al. New methodologic approaches for immunophenotyping acute leukemias. Haematologica. 2001;86:675-692
  • 6Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.Arch Pathol Lab Med,2003;127:42-48
  • 7Lee JJ, Cho D, Chung IJ, et al. CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia.Am J Hematol,2003;73:149-153
  • 8Pitha-Rowe I, Petty WJ, Kitareewan S, et al. Retinoid target genes in acute promyelocytic leukemia. Leukemia,2003;17:1723-1730
  • 9任汉云,中华血液学杂志,1991年,12卷,10期,505页
  • 10Harris NL,Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietie and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 [ J ]. J Clin Oncol, 1999,17 ( 12 ) : 3835-3849.

共引文献61

同被引文献12

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部